Skip to main content
    L

    LivaNova PLC (LIVN)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $92.44
    +1.12 (+1.23%)

    Market Cap: $5.03B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    LivaNova PLC (LIVN) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    LivaNova (LIVN) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, LivaNova reported EPS of $1.03, above the $0.90 estimate. It beat the EPS estimate in each of the last 18 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +18.76%
    Streak
    18 Q

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.00
    Range$0.92 - $1.16
    12 analysts
    Revenue Consensus
    $396.96M
    Range$377.99M - $414.75M
    11 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.06
    Range$0.99 - $1.13
    6 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$1.07-1.0%
    60d ago$1.07-1.0%
    30d ago$1.07-0.9%
    7d ago$1.07-0.9%
    Current$1.06
    Revenue Consensus
    $386.54M
    Range$384.90M - $389.40M
    5 analysts

    Next Report

    LIVN has an expected report date of Feb 23, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 16.3% above the $0.86 reported for the quarter ended Dec 31, 2025.

    LIVN Earnings Call

    The latest LIVN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, LIVN beat 36, missed 3 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $393.10M, up 9.9% from $357.80M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.03$0.90N/A+14.44%Beat+6.2%102 up, 7 downNov 4, 2026$393.10M
    Jun 30, 2026$1.02$0.96N/A+6.25%Beat-2.9%9N/AAug 5, 2026$390.60M
    Mar 31, 2026$0.98$0.90$0.75 - $1.03+8.89%Beat+11.4%100 up, 1 downMay 6, 2026$362.26M
    Dec 31, 2025$0.86$0.81$0.78 - $0.86+6.12%Beat+6.2%102 up, 0 downFeb 25, 2026$360.86M
    Sep 30, 2025$0.97$0.78N/A+24.36%Beat+7.8%90 up, 1 downNov 5, 2025$357.80M
    Jun 30, 2025$1.05$0.87$0.82 - $0.97+20.69%Beat+12.9%92 up, 7 downAug 6, 2025$352.52M
    Mar 31, 2025$0.88$0.76$0.69 - $0.83+15.79%Beat+20.5%9N/AMay 7, 2025$316.86M
    Dec 31, 2024$0.81$0.80$0.75 - $0.88+1.17%Beat-6.9%90 up, 0 downFeb 25, 2025$321.83M
    Sep 30, 2024$0.90$0.72$0.70 - $0.75+25.00%Beat+23.3%91 up, 0 downOct 30, 2024$318.12M
    Jun 30, 2024$0.93$0.78$0.72 - $0.80+19.23%Beat+19.2%70 up, 0 downJul 31, 2024$318.57M
    Mar 31, 2024$0.73$0.49$0.43 - $0.53+48.98%Beat+69.8%80 up, 0 downMay 1, 2024$294.91M
    Dec 31, 2023$0.87$0.77$0.73 - $0.86+12.99%Beat+7.4%80 up, 1 downFeb 21, 2024$310.13M
    Sep 30, 2023$0.73$0.64$0.59 - $0.74+14.06%Beat+25.9%80 up, 0 downNov 1, 2023$286.11M
    Jun 30, 2023$0.78$0.54$0.45 - $0.61+44.44%Beat+47.2%80 up, 0 downJul 26, 2023$293.88M
    Mar 31, 2023$0.43$0.39$0.35 - $0.50+10.26%Beat-10.4%70 up, 0 downMay 3, 2023$263.42M
    Dec 31, 2022$0.81$0.73$0.66 - $0.78+10.96%Beat+42.1%60 up, 0 downFeb 22, 2023$274.87M
    Sep 30, 2022$0.58$0.55$0.51 - $0.60+5.45%Beat-14.7%60 up, 0 downNov 2, 2022$252.60M
    Jun 30, 2022$0.53$0.52$0.50 - $0.56+1.92%Beat+1.9%60 up, 0 downAug 3, 2022$254.15M
    Mar 31, 2022$0.48$0.48$0.40 - $0.550.00%In line+37.1%60 up, 0 downMay 4, 2022$240.18M
    Dec 31, 2021$0.57$0.52$0.49 - $0.54+9.62%Beat-19.7%60 up, 0 downFeb 23, 2022$270.06M
    Sep 30, 2021$0.68$0.44$0.42 - $0.48+54.55%Beat+78.9%6N/ANov 3, 2021$253.22M
    Jun 30, 2021$0.52$0.33$0.29 - $0.37+57.58%BeatN/A6N/AJul 28, 2021$264.48M
    Mar 31, 2021$0.35$0.15$0.14 - $0.17+133.33%Beat+6.1%6N/AApr 28, 2021$247.60M
    Dec 31, 2020$0.71$0.68$0.64 - $0.70+4.41%Beat-29.0%6N/AFeb 24, 2021$269.56M
    Sep 30, 2020$0.38$0.20$0.11 - $0.29+90.00%Beat-54.8%6N/AOct 29, 2020$240.08M
    Jun 30, 2020-$0.15-$0.30-$0.33 - -$0.26+50.00%Beat-121.4%5N/AJul 29, 2020$182.21M
    Mar 31, 2020$0.33$0.43-$0.14 - $0.59-23.26%Miss-38.9%5N/AApr 29, 2020$242.40M
    Dec 31, 2019$1.00$0.98$0.92 - $1.05+2.04%Beat-10.7%6N/AFeb 26, 2020$287.60M
    Sep 30, 2019$0.84$0.75$0.70 - $0.78+12.00%Beat+7.7%7N/AOct 30, 2019$268.61M
    Jun 30, 2019$0.70$0.65$0.60 - $0.70+7.69%Beat-27.1%7N/AJul 31, 2019$277.17M
    Mar 31, 2019$0.54$0.56$0.42 - $0.69-3.57%Miss-20.6%8N/AMay 1, 2019$250.80M
    Dec 31, 2018$1.12$1.10$1.07 - $1.18+1.82%Beat+25.8%7N/AFeb 27, 2019$297.00M
    Sep 30, 2018$0.78$0.90$0.82 - $0.96-13.33%Miss-16.1%6N/AOct 31, 2018$272.08M
    Jun 30, 2018$0.96$0.92$0.88 - $0.94+4.35%Beat-5.0%6N/AAug 1, 2018$287.50M
    Mar 31, 2018$0.68$0.65$0.58 - $0.71+4.62%Beat-4.2%5N/AMay 2, 2018$250.40M
    Dec 31, 2017$0.89$0.77$0.72 - $0.82+15.58%Beat+4.7%4N/AFeb 28, 2018$278.40M
    Sep 30, 2017$0.93$0.78$0.75 - $0.80+19.23%Beat+82.4%5N/ANov 2, 2017$309.66M
    Jun 30, 2017$1.01$0.83$0.81 - $0.83+21.69%Beat+60.3%3N/AAug 9, 2017$321.39M
    Mar 31, 2017$0.71$0.67N/A+5.97%Beat+31.5%N/AN/AMay 3, 2017$285.11M
    Dec 31, 2016$0.85$0.81N/A+4.94%BeatN/AN/AN/AMar 1, 2017$310.60M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.76, up 11.6% from the year before. It was $2.53 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.76+11.6%
    Dec 31, 2024$3.37+19.9%
    Dec 31, 2023$2.81+17.1%
    Dec 31, 2022$2.40+13.2%
    Dec 31, 2021$2.12+66.9%
    Dec 31, 2020$1.27-58.8%
    Dec 31, 2019$3.08-13.0%
    Dec 31, 2018$3.54N/A
    Dec 31, 2017$3.54+39.9%
    Dec 31, 2016$2.53N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,900 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,94912
    2026Q2Jun 30, 20266,14713
    2026Q1Mar 31, 20266,56012
    2025Q4Dec 31, 20256,09511
    2025Q3Sep 30, 20256,51815
    2025Q2Jun 30, 20257,68713
    2025Q1Mar 31, 20257,84113
    2024Q3Sep 30, 20246,84913

    2026Q3 Earnings Call

    Opening remarks

    Briana Gotlin Vice President of Investor Relations Thank you, and welcome to our conference call and webcast discussing LivaNova's financial results for the third quarter of 2026. Joining me on today's call are Vladimir A. Makatsaria, our executive officer and member of the Board of Directors; Alex Shvartsburg, our Chief Financial Officer; and Ahmet Tezel, our Chief Innovation Officer. Before we begin, I would like to remind you that discussions during this call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings and documents furnished to the SEC, including today's press release, which is available on our website. We do not undertake to update any forward-looking statement. Also, the discussions will include certain non-GAAP financial measures with respect to performance, including, but not limited to, revenue results, which will be stated on a constant currency basis. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release, which is available on our website. We have also posted a presentation to our website that summarizes the points of today's call. This presentation is complementary to the other call materials and should be used as an enhanced communication tool. You can find the presentation and the press release in the Investors section of our website under News, Events and Presentations at investor.livanova.com. With that, I will turn the call over to Vladimir.

    Vladimir A. Makatsaria CEO Thank you, Briana. And thank you, everyone, for joining us today. Welcome to LivaNova's conference call for the third quarter of 2026. LivaNova delivered another quarter of double-digit revenue growth, with strength across all regions, driven by commercial execution and healthy demand for our cardiopulmonary and epilepsy technologies. Our core businesses continue to fuel both current performance and disciplined investment, enabling us to further strengthen our existing franchises while advancing new growth opportunities such as obstructive sleep apnea, or OSA. As we prepare to enter this attractive, high-growth, high-margin market, our team is focused on building a strong foundation for long-term success in OSA. Importantly, we are not building from the ground up. We are leveraging our neuromodulation capabilities developed through our epilepsy business, including product development expertise, established supply chain infrastructure, a global footprint, and market access competencies. To complement these existing strengths, we have also made key hires across the OSA commercial leadership team, adding targeted expertise as we prepare for commercialization. The strength of LivaNova's capabilities supports future market access for proximal hypoglossal nerve stimulation, or pHGNS. Recently, LivaNova contributed its robust clinical evidence to the CPT code application reviewed by the AMA editorial panel. Our OSPREY randomized controlled trial provided Level 1 evidence to support this application.

    Frequently Asked Questions About LIVN

    When is LivaNova's next earnings date?

    LivaNova's next earnings report is expected for Feb 23, 2027.

    Did LIVN beat earnings estimates last quarter?

    Yes. LivaNova reported EPS of $1.03 for the quarter ended Sep 30, 2026, above the $0.90 estimate, a 14.44% surprise.

    What EPS do analysts expect from LIVN next quarter?

    The consensus EPS estimate for LivaNova for the quarter ending Dec 31, 2026 is $1.00 from 12 analysts, with estimates from $0.92 to $1.16.

    How often does LIVN beat earnings estimates?

    LivaNova beat the EPS estimate in each of the last 18 quarters, with an average surprise of +16.17%.